Advertising reviews at the US FDA's Office of Prescription Drug Promotion (OPDP) are on pace to decline significantly by the end of the fiscal year, although the agency argues it is only a piece of its compliance effort.
Through the first half of fiscal year 2017, OPDP reported completing 39 reviews of promotional materials, putting it on pace to complete 78 by the end of the period, according to data from the agency's performance site FDA-TRACK
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?